BioScrip Inc (BIOS) Expected to Post Earnings of -$0.03 Per Share

Brokerages forecast that BioScrip Inc (NASDAQ:BIOS) will post earnings of ($0.03) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for BioScrip’s earnings, with the lowest EPS estimate coming in at ($0.04) and the highest estimate coming in at ($0.01). BioScrip posted earnings of ($0.15) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 80%. The firm is scheduled to report its next earnings report on Thursday, March 14th.

According to Zacks, analysts expect that BioScrip will report full year earnings of ($0.33) per share for the current year, with EPS estimates ranging from ($0.34) to ($0.31). For the next year, analysts forecast that the firm will report earnings of ($0.18) per share, with EPS estimates ranging from ($0.23) to ($0.14). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for BioScrip.

BioScrip (NASDAQ:BIOS) last announced its earnings results on Tuesday, November 6th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The company had revenue of $181.00 million during the quarter, compared to analyst estimates of $171.35 million. The business’s revenue for the quarter was down 8.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.12) EPS.

BIOS has been the topic of several analyst reports. Lake Street Capital raised their target price on BioScrip from $4.50 to $10.00 and gave the company a “buy” rating in a report on Friday, December 7th. Canaccord Genuity initiated coverage on BioScrip in a report on Wednesday, December 12th. They set a “buy” rating and a $5.00 target price on the stock. BidaskClub upgraded BioScrip from a “buy” rating to a “strong-buy” rating in a report on Friday, September 21st. Barrington Research reiterated a “buy” rating and set a $4.00 target price on shares of BioScrip in a report on Friday, October 5th. Finally, TheStreet upgraded BioScrip from a “d+” rating to a “c-” rating in a report on Monday, November 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. BioScrip presently has an average rating of “Buy” and an average target price of $4.88.

A number of hedge funds and other institutional investors have recently modified their holdings of BIOS. Metropolitan Life Insurance Co. NY grew its stake in BioScrip by 77.3% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 45,013 shares of the company’s stock valued at $132,000 after purchasing an additional 19,625 shares in the last quarter. Engineers Gate Manager LP acquired a new stake in BioScrip during the 3rd quarter valued at approximately $146,000. MetLife Investment Advisors LLC grew its stake in BioScrip by 220.8% during the 2nd quarter. MetLife Investment Advisors LLC now owns 64,727 shares of the company’s stock valued at $190,000 after purchasing an additional 44,548 shares in the last quarter. Citadel Advisors LLC grew its stake in BioScrip by 471.9% during the 3rd quarter. Citadel Advisors LLC now owns 66,502 shares of the company’s stock valued at $206,000 after purchasing an additional 54,874 shares in the last quarter. Finally, B. Riley Wealth Management Inc. acquired a new stake in BioScrip during the 3rd quarter valued at approximately $326,000. Hedge funds and other institutional investors own 82.09% of the company’s stock.

Shares of NASDAQ:BIOS traded down $0.13 during mid-day trading on Thursday, hitting $3.86. 907,036 shares of the company traded hands, compared to its average volume of 875,525. The company has a market cap of $437.90 million, a P/E ratio of -8.77 and a beta of 0.61. BioScrip has a 52-week low of $2.31 and a 52-week high of $4.14.

About BioScrip

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Recommended Story: How is the discount rate different from the Federal Funds rate?

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit